Meir Azulay

Meir Azulay is an enthusiastic entrepreneur and inventor with a rich background in the biotech industry. With decades of experience in biopharma, including time at MerckSerono, he has been involved in the development and manufacturing of Rebif, a well-known treatment for multiple sclerosis.

Meir Azulay holds a Master's degree in biochemistry from The Hebrew University in Jerusalem. Since 2005, he has served as the founder and CEO of a Contract Development and Manufacturing Organization (CDMO) company.

Throughout his career, Meir Azulay has been a key figure in various biotech companies, holding roles such as CEO at BPL Biologics, Co-founder and Director at Ammy-Bio Ltd, Managing Director at Bio-XL, and Co-Founder at Enzymogen, AMP Bio, NES Pharma, and more. He has also worked as a consultant, mentor, and service provider in the industry, contributing to the development of cutting-edge technologies that have reached commercialization or clinical trial stages.